| アブストラクト | Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) semaglutide, liraglutide, and dulaglutide are indicated for diabetes. Semaglutide and liraglutide were also approved for therapy of obesity or weight control. Apprehension has been expressed about the possible link between GLP-1 RAs and suicidality. Drug agencies established no causal relationship, but declaring that this risk cannot be underevaluated. We analyzed spontaneous signals of suspected adverse reactions (SARs) to liraglutide, semaglutide, and dulaglutide from EudraVigilance database for the years 2020-2025, to give a contribution in the definition of safety profile of GLP-1 RAs. SARs to semaglutide, liraglutide, and dulaglutide were analyzed, and descriptive and disproportionality analysis for adverse reactions was performed. Eye disorders were more frequently reported with semaglutide than liraglutide (ROR 2.67; 95% CI 1.54-4.63) and dulaglutide (ROR 1.89; 95% CI 1.30-2.75). Suicidal ideation was disproportionately reported with semaglutide (ROR 6.49; 95% CI 1.57-26.81) and liraglutide (ROR 8.61; 95% CI 1.87-39.45) compared with dulaglutide. Data suggest the need of further research and vigilance on the potential occurrence of eye disorders related to GLP-1 RAs semaglutide and liraglutide use and suggest not to underestimate the possibility of a link between these two drugs and suicidality. Caution is suggested when GLP-1 RAs are prescribed for patients characterized by ophthalmic and neuropsychiatric vulnerability. |
|---|
| ジャーナル名 | Naunyn-Schmiedeberg's archives of pharmacology |
|---|
| Pubmed追加日 | 2026/8/22 |
|---|
| 投稿者 | Ammendolia, Ilaria; Mondello, Cristina; Esposito, Emanuela; Calapai, Gioacchino; Curro, Mariaconcetta; Midiri, Paola; Firenzuoli, Bernardo; Noto, Alberto; Cancellieri, Antonino; Cardia, Luigi; Ardizzone, Alessio; Calapai, Fabrizio |
|---|
| 組織名 | Simple Departmental Unit of Pharmacy, IRCCS Centro Neurolesi "Bonino-Pulejo",;Messina, Italy.;Department of Chemical, Biological, Pharmaceutical and Environmental Sciences,;University of Messina, Messina, Italy.;Department of Biomedical and Dental Sciences and Morphological and Functional;Imaging, University of Messina, Messina, Italy.;Department of Clinical and Experimental Medicine, University of Messina, Messina,;Italy.;Department of Mental Health, AUSL Toscana Centro, UFSMIA, Valdinievole, Italy.;Department of Human Pathology of Adult and Childhood "Gaetano Barresi",;UniCamillus-Saint Camillus International University of Health Sciences, Rome,;Imaging, University of Messina, Messina, Italy. fabrizio.calapai@unime.it. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42629417/ |
|---|
